PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.65%
Positive revenue growth while MCHP is negative. John Neff might see a notable competitive edge here.
5.39%
Positive gross profit growth while MCHP is negative. John Neff would see a clear operational edge over the competitor.
44.97%
Positive EBIT growth while MCHP is negative. John Neff might see a substantial edge in operational management.
40.47%
Positive operating income growth while MCHP is negative. John Neff might view this as a competitive edge in operations.
75.78%
Positive net income growth while MCHP is negative. John Neff might see a big relative performance advantage.
78.95%
Positive EPS growth while MCHP is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
76.32%
Positive diluted EPS growth while MCHP is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.88%
Share reduction while MCHP is at 0.44%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.13%
Reduced diluted shares while MCHP is at 1.54%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.37%
Dividend growth at 75-90% of MCHP's 0.48%. Bill Ackman would press for a stronger return if the balance sheet allows.
78.07%
Positive OCF growth while MCHP is negative. John Neff would see this as a clear operational advantage vs. the competitor.
98.87%
Positive FCF growth while MCHP is negative. John Neff would see a strong competitive edge in net cash generation.
128.08%
10Y revenue/share CAGR at 75-90% of MCHP's 142.49%. Bill Ackman would press for new markets or product lines to narrow the gap.
16.05%
5Y revenue/share CAGR under 50% of MCHP's 47.61%. Michael Burry would suspect a significant competitive gap or product weakness.
30.73%
3Y revenue/share CAGR under 50% of MCHP's 62.64%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
221.77%
10Y OCF/share CAGR above 1.5x MCHP's 1.90%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-1.55%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
60.07%
3Y OCF/share CAGR under 50% of MCHP's 1919.61%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
530.73%
Net income/share CAGR above 1.5x MCHP's 243.47% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
26.69%
5Y net income/share CAGR 1.25-1.5x MCHP's 19.73%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
61.84%
3Y net income/share CAGR above 1.5x MCHP's 1.69%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
55.49%
10Y equity/share CAGR at 50-75% of MCHP's 90.70%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
28.39%
5Y equity/share CAGR above 1.5x MCHP's 15.65%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
34.19%
Below 50% of MCHP's 80.98%. Michael Burry suspects a serious short-term disadvantage in building book value.
707.91%
Dividend/share CAGR of 707.91% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
113.40%
5Y dividend/share CAGR above 1.5x MCHP's 39.39%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
56.13%
3Y dividend/share CAGR above 1.5x MCHP's 2.84%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-0.37%
Firm’s AR is declining while MCHP shows 4.82%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.96%
Inventory is declining while MCHP stands at 3.15%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
5.09%
Positive asset growth while MCHP is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.10%
BV/share growth above 1.5x MCHP's 1.52%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
20.99%
Debt growth far above MCHP's 0.56%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-3.54%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-0.66%
We cut SG&A while MCHP invests at 0.13%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.